LEADER 03287nam  2200781   450 
001 9910132261703321
005 20220504000034.0
010   $a3-527-67364-4
010   $a3-527-67366-0
035   $a(CKB)3710000000370188
035   $a(EBL)1977788
035   $a(SSID)ssj0001534291
035   $a(PQKBManifestationID)12590105
035   $a(PQKBTitleCode)TC0001534291
035   $a(PQKBWorkID)11494953
035   $a(PQKB)11705458
035   $a(MiAaPQ)EBC1977788
035   $a(Au-PeEL)EBL1977788
035   $a(CaPaEBR)ebr11048186
035   $a(CaONFJC)MIL769783
035   $a(OCoLC)904518353
035   $a(PPN)19641122X
035   $a(EXLCZ)993710000000370188
100   $a20150505h20152015  uy|            0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aAntitargets and drug safety /$fedited by La?slo? Urba?n, Vinod F. Patel, and Roy J. Vaz
210  1$aWeinheim, Germany :$cWiley-VCH,$d[2015]
210  4$dİ2015
215   $a1 online resource (1266 p.)
225 1 $aMethods and principles in medicinal chemistry ;$vvolume 66
300   $aDescription based upon print version of record.
311   $a3-527-67367-9 
311   $a3-527-33511-0 
320   $aIncludes bibliographical references and index.
327   $asection 1. General concept for target-based safety assessment -- section 2. Hepatic side effects -- section 3. Cardiovascular side effects -- section 4. Kinase antitargets -- section 5. Examples of clinical translation.
330   $aWith its focus on emerging concerns of kinase and GPCR-mediated antitarget effects, this vital reference for drug developers addresses one of the hot topics in drug safety now and in future. Divided into three major parts, the first section deals with novel technologies and includes the utility of adverse event reports to drug discovery, the translational aspects of preclinical safety findings, broader computational prediction of drug side-effects, and a description of the serotonergic system. The main part of the book looks at some of the most common antitarget-mediated side effects, focusing
410  0$aMethods and principles in medicinal chemistry ;$vv. 66.
606   $aDrugs$xSide effects
606   $aDrugs$xSide effects$xPrevention
606   $aDrug interactions
606   $aDrug development
606   $aDrugs$xStructure-activity relationships
606   $aDrug-Related Side Effects and Adverse Reactions
606   $aProtein Kinase Inhibitors$xadverse effects
606   $aPharmacovigilance
615  0$aDrugs$xSide effects.
615  0$aDrugs$xSide effects$xPrevention.
615  0$aDrug interactions.
615  0$aDrug development.
615  0$aDrugs$xStructure-activity relationships.
615 12$aDrug-Related Side Effects and Adverse Reactions.
615 22$aProtein Kinase Inhibitors$xadverse effects,
615 22$aPharmacovigilance.
676   $a615.19
702   $aUrba?n$b La?slo?
702   $aPatel$b Vinod F.
702   $aVaz$b Roy J.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910132261703321
996   $aAntitargets and drug safety$92286568
997   $aUNINA